Bimosiamose

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameBimosiamose
Drug Alias Name比莫西糖bimosiamosumbimosiamosebimosiamosaTBC-1269
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionLeukocyte adhesion molecule-1 inhibitorsP-selectin inhibitorsSelectin E inhibitors
TargetsLeukocyte adhesion molecule-1Selectin EP-selectin
Therapy Area/IndicationsPsoriasisPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEncysive
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRevotar Biopharmaceuticals Ag
Active IndicationsN/A
Inactive IndicationsPsoriasisPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksKEGG